H19 and Patent ductus arteriosus: Recently, a phase 1/2a clinical trial of intratumoral administration of BC-819, a DNA plasmid expressing diphtheria-toxin gene under the control of lncRNA H19 regulatory sequences, was carried out in patients with unresectable PDA and shown additional therapeutic benefit [131].